Besponsa FDA Approval History
FDA Approved: Yes (First approved August 17, 2017)
Brand name: Besponsa
Generic name: inotuzumab ozogamicin
Dosage form: for Injection
Company: Pfizer Inc.
Treatment for: Acute Lymphoblastic Leukemia
Besponsa (inotuzumab ozogamicin) is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Development timeline for Besponsa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.